Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology and women's health. Natera™ aims to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives.
Oncology:
The oncology portfolio includes Signatera™, a personalized, tumor-informed assay optimized to detect circulating tumor DNA (ctDNA) for molecular residual disease (MRD) assessment and recurrence monitoring for patients previously diagnosed with cancer.
When to use Signatera?
Women's Health:
Identify risk of severe genetic conditions helping families and treating physicians prepare early intervention thus improving outcomes.
Panorama: Next-Generation NIPT (Non-Invasive Prenatal Test)
Panorama is a blood-based genetic, prenatal screening test for pregnant women analyzing common chromosomal conditions affecting their baby's health. Panorama can be performed as early as 9 weeks of pregnancy.
The only SNP-based NIPT delivering more insights with high accuracy: Panorama is:
Panorama is based on SNPs (Single Nucleotide Polymorphism) evaluation— the 1% of human DNA that makes one person different from the another.
Horizon: a comprehensive, actionable carrier screening. Horizon helps couples determine the risk of passing on serious genetic conditions to their child. It can be performed either during preconception (ideally) or during pregnancy.